Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 11/20 | 0.42 |
| ▸ | PRKCI | P41743 | 3/20 | 0.41 |
| ▸ | BCDIN3D | Q7Z5W3 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | SELE | P16581 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122880 | 0.92 | MEN1 (0.46) | PRKCIICAM1SELEVCAM1MEN1 | |
| SCHEMBL5121947 | 0.91 | PDE5A (0.43) | PDE5ABCDIN3DMEN1KMT2A | |
| SCHEMBL5122355 | 0.90 | PDE5A (0.43) | PDE5ABCDIN3DMEN1KMT2A | |
| SCHEMBL5129789 | 0.90 | PRKCI (0.45) | PRKCIICAM1SELEVCAM1MEN1 | |
| SCHEMBL5118832 | 0.90 | PDE5A (0.46) | PDE5ABCDIN3D | |
| SCHEMBL5116761 | 0.85 | PDE5A (0.47) | PDE5ABCDIN3D | |
| SCHEMBL5118618 | 0.85 | PRKCI (0.59) | PDE5APRKCIBCDIN3DMEN1KMT2A | |
| SCHEMBL5115451 | 0.84 | MEN1 (0.46) | PDE5AMEN1KMT2A | |
| SCHEMBL5123252 | 0.84 | PDE5A (0.46) | PDE5AICAM1SELEVCAM1MEN1 | |
| SCHEMBL5127701 | 0.84 | PRKCI (0.47) | PRKCIICAM1SELEVCAM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | PDE5A 2002/4885PRKCI 1513/4885BCDIN3D 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.